Notice

Error
  • Error loading feed data

PRCSG News

ACR 2017 ABSTRACTS / POSTERS

  • Identification of Optimal Subcutaneous Doses of Tocilizumab in Children with Polyarticular-Course Juvenile Idiopathic Arthritis. Poster Session: Tuesday, November 7th, 9:00 AM - 11:00 AM

 

  • Safety of Adalimumab +/- Methotrexate for the Treatment of Polyarticular Juvenile Idiopathic Arthritis (pJIA): STRIVE Registry. Poster Session: Tuesday, November 7th, 9:00 AM - 11:00 AM

 

  • Long-Term Effectiveness and Safety of Abatacept in Juvenile Idiopathic Arthritis: Ongoing Results From the Abatacept in JIA Registry. Poster Session: Tuesday, November 7th, 9:00 AM - 11:00 AM

 

  • Subcutaneous Abatacept in Patients Aged 2 - 17 Years with Polyarticular Juvenile Idiopathic Arthritis and Inadequate Response to Biologic or Non-biologic Disease-Modifying Antirheumatic Drugs: Pharmacokinetics, Effectiveness, Safety and Immunogenicity Over 2 years. Oral Presentation: Tuesday, November 7th, 4:30 PM - 6:00 PM

 


 

March 2017 - Subcutaneous abatacept now available for patients with JIA. link

 

January 19, 2017 - HHS released revisions to the Common Rule aimed to enhance protections for research participants.

 

January 18, 2017 - New NIH Policy goes into effect: Dissemination of NIH-Funded Clinical Trial Information.

 

November 2016 - ICH released revised Guideline for Good Clinical Practice: ICH GCP E6(R2)